Sulfinpyrazone
Appearance
Clinical data | |
---|---|
Trade names | Apo-sulfinpyrazone |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682339 |
Routes of administration | oral intravenous |
ATC code | |
Pharmacokinetic data | |
Protein binding | 98–99% |
Metabolism | hepatic |
Excretion | renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.325 |
Chemical and physical data | |
Formula | C23H20N2O3S |
Molar mass | 404.48 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.
Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.
Contraindications
Sulfinpyrazone must not be used in persons with renal impairment or a high rate of excretion of uric acid (hyperuricosuria).[1]
Synthesis
References
- ^ Underwood M (2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.
{{cite journal}}
: Unknown parameter|month=
ignored (help)